May 13th 2024
Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Hanna Discusses Efficacy Results of Different Treatments in RET-Positive Lung Cancer
February 19th 2022During a Targeted Oncology case-based roundtable event, Nasser H. Hanna, MD, discussed the results of the LIBRETTO-001, ARROW, and other trials of patients with lung cancer with RET mutations or other biomarkers.
Read More
Is There a Future for Sintilimab/Chemo in US Patients With Nonsquamous NSCLC?
February 17th 2022Jorge Nieva, MD, discusses what’s needed for frontline sintilimab plus chemotherapy to have a future in United States patients with nonsquamous non–small cell lung cancer after a negative ODAC vote.
Read More
PD-L1 Inhibitor TQ-B2450 and Anlotinib Combo Is Promising in Second-Line NSCLC
February 16th 2022Positive phase 1 results of TQ-B2450 combined with anlotinib have lead to a phase 3 study of the combination versus pembrolizumab in patient with PD-L1 positive advanced non–small cell lung cancer.
Read More
ODAC Member Disagrees With Outcome for Sintilimab/Chemotherapy in Nonsquamous NSCLC
February 16th 2022In an interview with Targeted Oncology, Jorge Nieva, MD, provided a recap of the recent ODAC meeting and explained his stance against further research for frontline sintilimab plus chemotherapy for the treatment of patients with nonsquamous NSCLC.
Read More
FDA’s ODAC Votes No to Approval of Frontline Sintilimab/Chemotherapy in Nonsquamous NSCLC
February 10th 2022The FDA’s Oncologic Drug Advisory Committee has voted against approval of the biologics license application for sintilimab plus pemetrexed and platinum-based chemotherapy for the treatment of nonsquamous non–small cell lung cancer without further clinical trial research.
Read More
Roundtable Discussion: Dowlati Debates the Role of Osimertinib in Adjuvant Treatment of NSCLC
February 3rd 2022During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, and participants discussed the challenges of molecular testing and how to use test results to introduce targeted treatments for patients with non–small cell lung cancer.
Read More
Gadgeel Discusses Therapies for Patients With NSCLC and CNS Metastases
January 29th 2022During a Targeted Oncology case-based roundtable event, Shirish M Gadgeel, MD, discussed the results of the ALEX, ALTA-1L, and CROWN studies of immune checkpoint inhibitors in non–squamous non–small cell lung cancer.
Read More
FDA to Review sBLA for Frontline Cemiplimab Plus Chemotherapy in Advanced NSCLC
January 19th 2022The FDA is reviewing a supplemental biologics license application for cemiplimab-rwlc in combination with chemotherapy as a first-line treatment option for patients with advanced non-small cell lung cancer.
Read More
Hegde Considers Combination Regimens for NSCLC With PD-L1 Expression 1% or Higher
January 16th 2022During a Targeted Oncology live event, Aparna Hegde, MD, discussed the results of the KEYNOTE-189 study of pemetrexed and pembrolizumab, the KEYNOTE-042 study of single-agent pembrolizumab, and the CheckMate 227 study of nivolumab and ipilimumab in patients with non–small cell lung cancer.
Read More
Kim Discusses Multiple Immunotherapy Trials in PD-L1–Expressing NSCLC
January 7th 2022During a Targeted Oncology Case-Based Roundtable event, Chul Kim, MD, MPH, assistant professor at Georgetown University, discussed immunotherapy options for patients with non–small cell lung cancer with PD-L1 expression.
Read More
Optimal Adjuvant and Neoadjuvant Regimens Are Explored in Lung Cancer
December 29th 2021The most effective treatment strategy—adjuvant, neoadjuvant, or some combination of adjuvant plus neoadjuvant regimens— remains unclear. Ongoing trials are dedicated to defining the best sequence of treatment.
Read More
Roundtable Discussion: Experts Debate Types of Testing and Therapies in NSCLC
December 20th 2021Joel Neal, MD, PhD and Karen Kelly, MD recently teamed up to moderate a roundtable discussion around molecular testing and choice of treatment for a 59-year-old patient with non–small cell lung cancer.
Read More
Part 2: Rare Mutations and Non-Clinical Barriers for Molecular Testing in NSCLC
December 16th 2021During a live virtual event, Ravi Salgia, MD, PhD, discussed issues with molecular testing and biopsies including delays and affordability, plus identifying and responding to rare mutations detected by molecular testing.
Read More